NCT06835179 2025-02-19
SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting